Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality.

ABSTRACT:

Background

Metastatic breast cancer (BCa) is most often diagnosed months after completion of treatment of the primary tumor when a patient reports physical symptoms. Besides a physical examination, no other alternative recurrence screening method is recommended for routine follow-up care. Detection of autoantibodies against tumor-associated antigens (TAAs) has demonstrated promise for distinguishing healthy women from patients diagnosed with primary BCa. However, it is unknown what changes occur to patient autoantibody levels during and after treatment.

Methods

Three serial blood draws were collected from 200 BCa patients: before treatment, 6 and 12 months after surgery. Patients were categorized according to treatment regimen, including surgery, chemotherapy, radiation, tra

SUBMITTER: Evans RL 

PROVIDER: S-EPMC5793406 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature